DK0879056T3 - Modulation af Th1/Th2-cytokinekspression med ribavirin i aktiverede T-lymfocytter - Google Patents

Modulation af Th1/Th2-cytokinekspression med ribavirin i aktiverede T-lymfocytter

Info

Publication number
DK0879056T3
DK0879056T3 DK97904765T DK97904765T DK0879056T3 DK 0879056 T3 DK0879056 T3 DK 0879056T3 DK 97904765 T DK97904765 T DK 97904765T DK 97904765 T DK97904765 T DK 97904765T DK 0879056 T3 DK0879056 T3 DK 0879056T3
Authority
DK
Denmark
Prior art keywords
activated
ribavirin3
ribavirin
lymphocytes
modulation
Prior art date
Application number
DK97904765T
Other languages
English (en)
Inventor
Robert Tam
Kandsamy Ramasamy
Devron Averett
Original Assignee
Icn Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26712784&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0879056(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/590,449 external-priority patent/US5767097A/en
Application filed by Icn Pharmaceuticals filed Critical Icn Pharmaceuticals
Application granted granted Critical
Publication of DK0879056T3 publication Critical patent/DK0879056T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/052—Imidazole radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
DK97904765T 1996-01-23 1997-01-21 Modulation af Th1/Th2-cytokinekspression med ribavirin i aktiverede T-lymfocytter DK0879056T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/590,449 US5767097A (en) 1996-01-23 1996-01-23 Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
US3609497P 1997-01-17 1997-01-17
PCT/US1997/000600 WO1997026883A1 (en) 1996-01-23 1997-01-21 Modulation of th1/th2 cytokine expression by ribavirin® and ribavirin® analogs in activated t-lymphocytes

Publications (1)

Publication Number Publication Date
DK0879056T3 true DK0879056T3 (da) 2002-08-19

Family

ID=26712784

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97904765T DK0879056T3 (da) 1996-01-23 1997-01-21 Modulation af Th1/Th2-cytokinekspression med ribavirin i aktiverede T-lymfocytter

Country Status (21)

Country Link
EP (1) EP0879056B1 (da)
KR (1) KR100298158B1 (da)
CN (1) CN1190198C (da)
AT (1) ATE216886T1 (da)
BR (1) BR9707154A (da)
CA (1) CA2246162C (da)
CZ (1) CZ293584B6 (da)
DE (1) DE69712316T2 (da)
DK (1) DK0879056T3 (da)
ES (1) ES2172764T3 (da)
HU (1) HU220105B (da)
IL (1) IL125088A0 (da)
NO (1) NO983372L (da)
NZ (1) NZ330784A (da)
PL (1) PL187439B1 (da)
PT (1) PT879056E (da)
RU (1) RU2186569C2 (da)
SI (1) SI9720013A (da)
SK (1) SK283342B6 (da)
UA (1) UA46815C2 (da)
WO (1) WO1997026883A1 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1132393B1 (en) * 1996-10-16 2003-04-09 ICN Pharmaceuticals, Inc. L-Ribavirin and uses thereof
JP4391592B2 (ja) * 1996-10-25 2009-12-24 スリーエム カンパニー Ｔｈ２介在性および関連疾患治療のための免疫応答修飾化合物
CA2357735A1 (en) * 1999-01-29 2000-08-03 Icn Pharmaceuticals, Inc. Modulation of immune response by ribavirin
US6455508B1 (en) * 2000-02-15 2002-09-24 Kanda S. Ramasamy Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides
US7638496B2 (en) 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
US6858590B2 (en) 2000-08-17 2005-02-22 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
CN100400101C (zh) * 2000-08-17 2008-07-09 特里帕普股份公司 包含病毒唑的疫苗及其使用方法
US6680059B2 (en) 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
EP1450856B1 (en) 2001-09-14 2009-11-11 Cytos Biotechnology AG Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use
JP2006524227A (ja) * 2003-03-28 2006-10-26 ファーマセット，インク． フラビウイルス科ウイルス感染の治療のための化合物
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
EP1858535A4 (en) * 2005-02-25 2012-05-02 Efficas Inc COMPOSITIONS WITH ACTINIDIA AND METHOD OF USE THEREOF
AU2006325225B2 (en) 2005-12-14 2013-07-04 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
AU2007222135B2 (en) * 2006-03-09 2012-02-02 Om Pharma Immunomodulatory compounds and treatment of diseases related to an overproduction of inflammatory cytokines
SI2032592T1 (sl) 2006-06-12 2013-10-30 Cytos Biotechnology Ag Postopki za pakiranje oligonukleotidov v virusu-podobne delce RNA bakteriofagov
WO2009022236A2 (en) 2007-08-16 2009-02-19 Tripep Ab Immunogen platform
KR102072041B1 (ko) 2011-12-22 2020-01-31 앨리오스 바이오파마 인크. 치환된 뉴클레오사이드, 뉴클레오타이드 및 그의 유사체
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
PT2861611T (pt) 2012-05-25 2016-10-11 Janssen Sciences Ireland Uc Nucleósidos de espirooxetano de uracilo
US9243022B2 (en) 2012-12-21 2016-01-26 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CN105829333A (zh) 2013-10-11 2016-08-03 艾丽奥斯生物制药有限公司 取代的核苷、核苷酸及其类似物
WO2015175861A1 (en) 2014-05-16 2015-11-19 Amgen Inc. Assay for detecting th1 and th2 cell populations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI875245A0 (fi) * 1986-03-27 1987-11-27 Harry Edward Gruber Foerfarande foer oekande av utsoendringen av adenosin.
NZ229453A (en) * 1988-06-10 1991-08-27 Univ Minnesota & Southern Rese A pharmaceutical composition containing purine derivatives with nucleosides such as azt, as antiviral agents
JPH06507404A (ja) * 1991-05-01 1994-08-25 ヘンリー　エム．ジャクソン　ファウンデイション　フォー　ザ　アドバンスメント　オブ　ミリタリー　メディスン 感染性の呼吸性疾患の治療方法
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection

Also Published As

Publication number Publication date
CZ232998A3 (cs) 1999-04-14
HU220105B (hu) 2001-10-28
HUP9900681A3 (en) 1999-12-28
BR9707154A (pt) 1999-05-25
ES2172764T3 (es) 2002-10-01
EP0879056A1 (en) 1998-11-25
UA46815C2 (uk) 2002-06-17
SK100498A3 (en) 2001-03-12
NO983372D0 (no) 1998-07-22
KR100298158B1 (ko) 2001-09-06
RU2186569C2 (ru) 2002-08-10
AU700642B2 (en) 1999-01-14
PT879056E (pt) 2002-10-31
DE69712316T2 (de) 2003-01-02
CA2246162C (en) 2000-04-04
SI9720013A (sl) 1999-06-30
CN1209747A (zh) 1999-03-03
EP0879056B1 (en) 2002-05-02
EP0879056A4 (en) 1999-01-13
CN1190198C (zh) 2005-02-23
CA2246162A1 (en) 1997-07-31
PL328003A1 (en) 1999-01-04
SK283342B6 (sk) 2003-06-03
AU1747897A (en) 1997-08-20
NO983372L (no) 1998-09-21
DE69712316D1 (en) 2002-06-06
HUP9900681A2 (hu) 1999-07-28
CZ293584B6 (cs) 2004-06-16
PL187439B1 (pl) 2004-07-30
WO1997026883A1 (en) 1997-07-31
KR19990081930A (ko) 1999-11-15
ATE216886T1 (de) 2002-05-15
NZ330784A (en) 1999-02-25
IL125088A0 (en) 1999-01-26

Similar Documents

Publication Publication Date Title
ATE216886T1 (de) Modulation der th1/th2 cytokinexpression durch ribavirin in aktivierten t-lymphozyten
AU6385486A (en) Sustained release composition
ATE49126T1 (de) Mittel zur transdermalen applikation von arzneistoffen.
DE59007178D1 (de) Verwendung alkylierter Polyethylenimine als gallensäureadsorbierende Arzneimittel sowie pharmazeutische Präparate.
ATE61227T1 (de) Menschliche komplementfaktoren und ihre therapeutische verwendung.
ES2139574T3 (es) Nuevos gases propulsores y su uso en preparaciones medicas.
DE3752112D1 (de) Verwendung von Inositoltriphosphat zur Behandlung von Entzündungen
BR9814957A (pt) Tratamento de doenças imune mediadas por célula auxiliar "t" tipo 2 com antagonistas retinóides
DK0839026T3 (da) Micellære polyether-blokcopolymerkompositioner til målretning af biologiske midler
ES290656Y (es) Dispositivo para recoger y mantener vivos los cultivos del cuerpo del paciente.
ES2197500T3 (es) Uso de cloruro de n,n-bis(fenilcarbamoilmetil)dimetilamonio y sus usos derivados en el tratamiento del dolor cronico.
ES2151607T3 (es) Factor 12 de crecimiento y de diferenciacion.
DE3671763D1 (de) Bipolare elektrolysevorrichtung und einheitszelle fuer diese.
ES2168457T3 (es) Composiciones farmaceuticas que comprenden una superoxido dismutasa.
DK0951553T3 (da) Adenovirus-E4-proteiner til induktion af celledød
FI971097A0 (fi) Skopolamiinilaastari
ES2036526T3 (es) Composiciones de interferon.
EP1240899A3 (en) Modulation of Th1/Th2 Cytokine expression by Ribavirin and Ribavirin analogs in actived T-Lymphocytes for treating HCV infections
ATE84058T1 (de) Gel-zusammensetzung.
ATE62789T1 (de) Mittel zur bekaempfung von phytopathogenen mikroben.
ES8704903A1 (es) Un metodo para preparar 6-cloro-2-metil-1h-2,3,4,5-tetrahidro-3-benzazepen-n-oxido.
DK369886A (da) Hidtil ukendte acylphosphotriamider og pharmaceutisk komposition indeholdende samme til aendring af lipidindholdet i blodplasma hospattedyr
EP1174141A3 (en) Modulation of TH1/TH2 cytokine expression by ribavirin and ribavirin analogs in activated t-lymphocytes
ES2026966T3 (es) Procedimiento para la obtencion de 4-metil-4-fenil-1-penta--nales y su empleo como perfumantes.
ATE87207T1 (de) Azapropazon zur praevention von post-ischaemischem gewebeschaden.